Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

14 May 2015 07:00

RNS Number : 1134N
Ideagen PLC
14 May 2015
 

 

 

Ideagen plc

("Ideagen" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces a trading update for the year ended 30 April 2015.

 

Trading for the year to 30 April 2015 was robust and in line with expectations with both continued organic growth and contributions from EIBS and Gael. The results will therefore show the Group's sixth consecutive year of revenue and EBITDA* growth, with revenue expected to be up 59 per cent. to approximately £14.3 million and adjusted EBITDA expected to be up by 42 per cent. to approximately £4 million. This will lead to a significant increase in adjusted EPS** which continues to be an important financial metric for the Group and has averaged growth of 24 per cent. per annum since 2012.

 

Cash at 30 April was £5.25m and with no debt our strong balance sheet provides the Group with the capacity to pursue further strategic opportunities in the current financial year.

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and exceptional items.

** Adjusted fully diluted earnings per share,

 

Performance and Integration of Gael

 

The acquisition of Gael has transformed the Group and has made a strong and positive contribution both financially and in terms of product capability. Integration is well underway and a number of existing Ideagen customers have upgraded their existing installations to take advantage of the enhanced proposition that the Group can now offer. Having successfully executed our immediate objectives we can now accelerate the integration of Gael into the Group. To enable this Ashley Marron, Chief Executive of Gael has been appointed Group Chief Operating Officer with responsibility for all of Ideagen's Product Strategy and Development and Customer Services.

 

Outlook

 

The Group has significant contracted work in progress, a growing recurring revenue base and a strong pipeline of new business. We have experienced robust growth within our Commercial Markets such as Manufacturing, Life Sciences, Aviation and Banking which, we expect to continue. We are also seeing renewed momentum within a number of sales opportunities at NHS Hospital Trusts, which had slowed prior to the election. The Board is therefore confident that the Group will continue to meet its growth objectives for this financial year and beyond.

 

David Hornsby, Chief Executive, commented: "The Group has once again met market expectations, demonstrating the strength of our business model and products and the talent and dedication of our employees. I am delighted with the contribution from our newly acquired businesses, Gael and EIBS, and look forward to an exciting year ahead

 

 

 

Enquiries:

Ideagen Plc

Tel: 01629 699100

David Hornsby (Chief Executive)

 

Graeme Spenceley (Finance Director)

 

 

 

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews, James Thompson (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQXLFFEEFBBBE
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.